Legal & General Group Plc lessened its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 40.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 851,421 shares of the company's stock after selling 579,011 shares during the period. Legal & General Group Plc owned 1.48% of Ginkgo Bioworks worth $8,369,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in Ginkgo Bioworks during the 4th quarter valued at about $29,000. KBC Group NV purchased a new stake in Ginkgo Bioworks in the 4th quarter worth approximately $31,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Ginkgo Bioworks during the 4th quarter worth approximately $46,000. Palumbo Wealth Management LLC acquired a new position in shares of Ginkgo Bioworks in the 4th quarter valued at $144,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Ginkgo Bioworks during the fourth quarter worth $154,000. 78.63% of the stock is currently owned by institutional investors.
Ginkgo Bioworks Trading Up 0.7 %
DNA traded up $0.05 on Thursday, reaching $7.65. The stock had a trading volume of 459,225 shares, compared to its average volume of 1,493,232. The company has a market cap of $443.96 million, a P/E ratio of -0.58 and a beta of 1.34. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.00 and a 12-month high of $45.20. The business's 50-day moving average price is $7.88 and its two-hundred day moving average price is $9.14.
Ginkgo Bioworks Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
